NCT04774952 2025-04-15Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Completed58 enrolled
NCT01320085 2024-01-24A Phase II Study of Single Agent MEK162 in Patients With Advanced MelanomaPfizerPhase 2 Completed183 enrolled 35 charts